General Information of Drug (ID: DMLRQH0)

Drug Name
Indirubin-3'-monoxime Drug Info
Synonyms
INDIRUBIN-3'-MONOXIME; indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3& CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070; Indirubin-3-oxime
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3707
ChEBI ID
CHEBI:43645
CAS Number
CAS 160807-49-8
TTD Drug ID
DMLRQH0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Patented Agent(s)
Preclinical Drug(s)
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [8]
Roscovitine derivative 1 DMD1G3Z N. A. N. A. Patented [9]
Tricyclic benzimidazole derivative 1 DM5SD9E N. A. N. A. Patented [9]
4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN N. A. N. A. Patented [9]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW N. A. N. A. Patented [9]
Naphthyridine and isoquinoline derivative 1 DMTGIP7 N. A. N. A. Patented [9]
PMID26161698-Compound-18 DM6JVR5 N. A. N. A. Patented [9]
Flavonoid derivative 7 DM6A9UR N. A. N. A. Patented [9]
L-751250 DMOERXK Obesity 5B81 Preclinical [4]
Olomoucine DMNAFG1 N. A. N. A. Terminated [4]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [10]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [10]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [12]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [13]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [9]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [15]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [16]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [10]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
PHA848125 DMS2Q9G Thymic cancer 2C27 Phase 2 [17]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [18]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [19]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [13]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [20]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [22]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [23]
6-bromoindirubin-3-oxime DM12WYV Discovery agent N.A. Investigative [2]
7-fluoroindirubin-3-oxime DMQD34N Discovery agent N.A. Investigative [2]
PMID21742770C1 DME3JMH Discovery agent N.A. Investigative [24]
Indirubin-3-acetoxime DM3UR1E Discovery agent N.A. Investigative [2]
CGP-57380 DMFPOUC Discovery agent N.A. Investigative [23]
PMID20855207C25 DMNEB6J Discovery agent N.A. Investigative [25]
Indirubin-3-methoxime DMZ5ODC Discovery agent N.A. Investigative [2]
4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine DM9MPHF Discovery agent N.A. Investigative [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora kinase A (AURKA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT9283 DMQ94CT Solid tumour/cancer 2A00-2F9Z Phase 3 [27]
MLN8237 DMO8PT9 Solid tumour/cancer 2A00-2F9Z Phase 3 [28]
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [10]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [29]
ENMD-2076 DMJZVPB Acute myeloid leukaemia 2A60 Phase 2 [10]
LY3295668 DM8RJTB Solid tumour/cancer 2A00-2F9Z Phase 1/2 [30]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [31]
MLN8054 DMUANF3 Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
CYC116 DMUMHXT Solid tumour/cancer 2A00-2F9Z Phase 1 [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora kinase C (AURKC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [22]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [29]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [31]
AMG 900 DMASGXJ Solid tumour/cancer 2A00-2F9Z Phase 1 [33]
SNS-314 DMAC5F2 Solid tumour/cancer 2A00-2F9Z Phase 1 [34]
GSK1070916 DMXRPT6 Advanced solid tumour 2A00-2F9Z Phase 1 [35]
GSK1070916A DMCJUI9 Solid tumour/cancer 2A00-2F9Z Phase 1 [35]
MK-6592 DMB5NOI Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [36]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [23]
6-bromoindirubin-3-oxime DM12WYV Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [37]
Ketoprofen DMRKXPT Bursitis Approved [38]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [39]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [40]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [43]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [44]
Acetic Acid, Glacial DM4SJ5Y infection in the ear canal AA0Y Approved [45]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [47]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [48]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [49]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [50]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [51]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [52]
Ethacrynic acid DM60QMR Edema MG29 Approved [53]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [54]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [55]
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [57]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [58]
Amlexanox DM0DQM5 Respiratory tract inflammation CA07 Approved [59]
Selenium DM25CGV N. A. N. A. Approved [60]
Methotrexate DM2TEOL Anterior urethra cancer Approved [61]
Quercetin DM3NC4M Obesity 5B81 Approved [62]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [52]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [63]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [64]
Aluminium DM6ECN9 Hyperhidrosis EE00 Approved [65]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [66]
Selenium DM25CGV N. A. N. A. Approved [67]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [52]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [68]
Leflunomide DMR8ONJ Arthritis FA20 Approved [69]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [70]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [71]
Gemfibrozil DMD8Q3J Hyperlipidaemia 5C80 Approved [72]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [72]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [73]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [67]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [74]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [75]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [70]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [76]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [77]
Gallium nitrate DMF9O6B Hypercalcaemia 5B91.0 Approved [78]
Clozapine DMFC71L Schizophrenia 6A20 Approved [79]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [80]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [81]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [67]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [52]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [54]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [70]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [82]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [83]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [80]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [84]
Arsenic DMTL2Y1 N. A. N. A. Approved [85]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [86]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Actin, cytoplasmic 1 (ACTB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [87]
Selenium DM25CGV N. A. N. A. Approved [67]
Etretinate DM2CZFA Keratosis ED56 Approved [88]
Quercetin DM3NC4M Obesity 5B81 Approved [89]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [74]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [90]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [91]
Leflunomide DMR8ONJ Arthritis FA20 Approved [69]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [89]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [71]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Apoptosis regulator BAX (BAX)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [92]
Aprepitant DM053KT Depression 6A70-6A7Z Approved [93]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [94]
Verapamil DMA7PEW Angina pectoris BA40 Approved [95]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [96]
Leuprorelin acetate DM15HAT Prostate cancer 2C82.0 Approved [97]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [98]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [87]
Meloxicam DM2AR7L Arthritis FA20 Approved [99]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [100]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [101]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [102]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [103]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [104]
Quercetin DM3NC4M Obesity 5B81 Approved [89]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [105]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [106]
Estrone DM5T6US Acne vulgaris ED80 Approved [101]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [107]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [108]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [109]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [110]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [111]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [75]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [112]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [113]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [71]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [114]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [115]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [116]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [117]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [118]
Selenium DM25CGV N. A. N. A. Approved [119]
Quercetin DM3NC4M Obesity 5B81 Approved [120]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [121]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [122]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [123]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [124]
Testosterone DM7HUNW Hot flushes GA30 Approved [125]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [126]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Androgen receptor (AR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [127]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [127]
Hydroxyflutamide DMGIZF5 Prostate cancer 2C82.0 Approved [127]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [128]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [129]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [130]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [131]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [132]
Selenium DM25CGV N. A. N. A. Approved [119]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [133]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [134]
Gefitinib DM15F0X Colon adenocarcinoma Approved [135]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [136]
Selenium DM25CGV N. A. N. A. Approved [67]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [137]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [138]
Quercetin DM3NC4M Obesity 5B81 Approved [139]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [140]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [74]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [141]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aurora B messenger RNA (AURKB mRNA) TT9RTBL AURKB_HUMAN Inhibitor [2]
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Inhibitor [2]
Aurora kinase C (AURKC) TTLYXIT AURKC_HUMAN Inhibitor [2]
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Binder [3]
Cyclin-dependent kinase 2 (CDK2) TT7HF4W CDK2_HUMAN Inhibitor [4]
Cyclin-dependent kinase 5 (CDK5) TTL4Q97 CDK5_HUMAN Inhibitor [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Actin, cytoplasmic 1 (ACTB) OT1MCP2F ACTB_HUMAN Gene/Protein Processing [5]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Gene/Protein Processing [6]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [5]
Bifunctional epoxide hydrolase 2 (EPHX2) OTPTRCNW HYES_HUMAN Gene/Protein Processing [5]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [5]
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Gene/Protein Processing [5]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Gene/Protein Processing [5]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Gene/Protein Processing [7]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Gene/Protein Processing [6]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Gene/Protein Processing [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5989).
2 An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
3 The kinase inhibitor indirubin-3'-oxime prevents germinal vesicle breakdown and reduces parthenogenetic development of pig oocytes. Theriogenology. 2006 Mar 1;65(4):744-56.
4 Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
5 The effects of indirubin-3'-monoxime, a novel AHR ligand, on stress and toxicity-related gene/protein expression in human U937 cells undergoing differentiation and activation. J Immunotoxicol. 2006 Jan 1;3(1):1-10.
6 Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations. Chem Biol Interact. 2011 Feb 1;189(3):177-85. doi: 10.1016/j.cbi.2010.11.008. Epub 2010 Nov 25.
7 The specificities of protein kinase inhibitors: an update. Biochem J. 2003 Apr 1;371(Pt 1):199-204. doi: 10.1042/BJ20021535.
8 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
9 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
10 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
11 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
12 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
13 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
14 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
15 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
16 Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
17 Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
18 Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
19 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
20 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
21 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
22 Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
23 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
24 A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
25 Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
26 Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.
27 A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
28 Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
29 Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
30 Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
32 Clinical pipeline report, company report or official report of Cyclacel.
33 Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
34 SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
35 Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
36 Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009 Aug;14(8):780-93.
37 Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):117-27.
38 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
39 Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83. Int J Mol Sci. 2020 Aug 1;21(15):5533. doi: 10.3390/ijms21155533.
40 Comparison of characteristics of peroxide-conditioned immortal human lens-epithelial cell lines with their murine counterparts. Exp Eye Res. 2004 Sep;79(3):411-7.
41 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
42 Quercetin modulates Nrf2 and glutathione-related defenses in HepG2 cells: Involvement of p38. Chem Biol Interact. 2012 Jan 25;195(2):154-64.
43 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
44 Glutathione depletion in antioxidant defense of differentiated NT2-LHON cybrids. Neurobiol Dis. 2007 Mar;25(3):536-44.
45 Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
46 An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
47 Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
48 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
49 Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
50 Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
51 Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
52 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
53 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
54 Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
55 The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
56 Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
57 Chromium III histidinate exposure modulates gene expression in HaCaT human keratinocytes exposed to oxidative stress. Biol Trace Elem Res. 2010 Oct;137(1):23-39.
58 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
59 Premature termination codon readthrough in human cells occurs in novel cytoplasmic foci and requires UPF proteins. J Cell Sci. 2017 Sep 15;130(18):3009-3022. doi: 10.1242/jcs.198176. Epub 2017 Jul 25.
60 Effects of Se-depletion on glutathione peroxidase and selenoprotein W gene expression in the colon. FEBS Lett. 2005 Jan 31;579(3):792-6. doi: 10.1016/j.febslet.2004.12.042.
61 Methotrexate-related response on human peripheral blood mononuclear cells may be modulated by the Ala16Val-SOD2 gene polymorphism. PLoS One. 2014 Oct 20;9(10):e107299. doi: 10.1371/journal.pone.0107299. eCollection 2014.
62 A high-throughput reporter gene assay to prove the ability of natural compounds to modulate glutathione peroxidase, superoxide dismutase and catalase gene promoters in V79 cells. Free Radic Res. 2008 Aug;42(8):746-53.
63 Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
64 Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid. Acta Pharmacol Sin. 2006 Aug;27(8):1078-84.
65 Involvement of oxidative stress in the impairment in biliary secretory function induced by intraperitoneal administration of aluminum to rats. Biol Trace Elem Res. 2007 Jun;116(3):329-48.
66 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
67 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
68 Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
69 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
70 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
71 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
72 Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. Toxicol Appl Pharmacol. 2018 Sep 15;355:156-163.
73 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
74 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
75 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
76 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
77 Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia. EBioMedicine. 2017 Oct;24:147-158. doi: 10.1016/j.ebiom.2017.09.022. Epub 2017 Sep 19.
78 Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med. 2008 Sep 15;45(6):763-72.
79 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
80 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
81 Mitochondrial proteomics investigation of a cellular model of impaired dopamine homeostasis, an early step in Parkinson's disease pathogenesis. Mol Biosyst. 2014 Jun;10(6):1332-44.
82 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
83 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
84 Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells. Toxicol Lett. 2011 Sep 10;205(3):341-50. doi: 10.1016/j.toxlet.2011.06.028. Epub 2011 Jul 2.
85 Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci. 2001 Jan;59(1):185-92.
86 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
87 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
88 Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
89 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
90 Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol. 2002 Aug 9;449(3):197-205.
91 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
92 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
93 Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
94 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
95 Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
96 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
97 Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
98 BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
99 Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
100 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
101 Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
102 A novel, integrated in vitro carcinogenicity test to identify genotoxic and non-genotoxic carcinogens using human lymphoblastoid cells. Arch Toxicol. 2018 Feb;92(2):935-951. doi: 10.1007/s00204-017-2102-y. Epub 2017 Nov 6.
103 A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
104 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
105 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
106 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
107 Gene expression profile of multiple myeloma cell line treated by arsenic trioxide. J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):646-9. doi: 10.1007/s11596-007-0606-z.
108 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
109 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
110 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
111 Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
112 Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
113 Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
114 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
115 Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
116 Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
117 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
118 Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
119 Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
120 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
121 EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
122 Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007 Aug 1;67(11):1152-62. doi: 10.1002/pros.20585.
123 Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
124 An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
125 Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
126 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
127 TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
128 Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
129 Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
130 Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
131 Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
132 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
133 Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
134 Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
135 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
136 The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem Biol Interact. 2019 Sep 1;310:108688. doi: 10.1016/j.cbi.2019.06.001. Epub 2019 Jun 4.
137 Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001 Sep 27;20(43):6250-7. doi: 10.1038/sj.onc.1204791.
138 Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
139 Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
140 Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact. 2010 Oct 6;188(1):75-85. doi: 10.1016/j.cbi.2010.06.001. Epub 2010 Jun 9.
141 NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity. J Biol Chem. 2021 Jan-Jun;296:100624. doi: 10.1016/j.jbc.2021.100624. Epub 2021 Apr 2.